The growth inhibitory role and potential clinical value of Macrophage Inflammatory Protein 1 alpha in myeloid leukaemias

P. J. Owen-Lynch, L. G. Czaplewski, M. G. Hunter, A. D. Whetton

Research output: Contribution to journalReview article

13 Citations (Scopus)


The control of primitive haemopoietic progenitor cell proliferation in vitro can be achieved with combinations of growth stimulatory cytokines. Acting in apparent opposition to these growth stimulators are growth inhibitory substances, including prostaglandins, cytokines and chemokines which bind to specific cognate cell surface receptors and promote signal transduction events that interfere with cellular proliferation. Within the bone marrow microenvironment, significant quantities of both growth inhibitors and growth promoters can be detected. The ratio of their concentrations within microenvironmental niches of the marrow may regulate primitive blood cell production. The potential exists, therefore, for the disregulation of haemopoiesis via the disruption of the balance between positive and negative regulators of haemopoietic progenitor proliferation. In one particular disease, chronic myeloid leukaemia (CML), there is a lack of response of leukaemic cells to the chemokine growth inhibitor, Macrophage Inflammatory Protein-1alpha (MIP-1alpha). The role of MIP-1alpha in regulation of haemopoiesis, the response of CML progenitor cells and other myeloid leukaemic cells to this chemokine, and the reasons for lack of response to MIP-1alpha in leukaemic cells are reviewed.

Original languageEnglish
Pages (from-to)41-53
Number of pages13
JournalLeukemia and Lymphoma
Issue number1-2
Publication statusPublished - 1 Jan 1998
Externally publishedYes


Cite this